InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Sunday, 03/20/2022 8:46:13 PM

Sunday, March 20, 2022 8:46:13 PM

Post# of 820
The company plans to initiate a clinical trial of the first TALEN-edited TIL therapy, IOV-4001 (PD-1 inactivated), this year for unresectable or metastatic melanoma and stage III or IV NSCLC, after the IND was accepted.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IOVA News